TY - JOUR
T1 - Translational medicine of the glutamate AMPA receptor
AU - MIYAZAKI, By Tomoyuki
AU - ABE, Hiroki
AU - UCHIDA, Hiroyuki
AU - TAKAHASHI, Takuya
N1 - Funding Information:
This work was supported by Special Coordination Funds for Promoting Science and Technology (T.T.), AMED under Grant Number JP19dm0107124 (T.T.), JP18dm0207023 (T.T.), JP19lm0203007 (T.T.), Takeda Science Foundation (T.T.), The Uehara Memorial Foundation (T.T.), and KAKENHI under grant number 20H00549 (T.T.).
Funding Information:
This work was supported by Special Coordina-
Publisher Copyright:
© 2021. The Japan Academy. All Rights Reserved.
PY - 2021
Y1 - 2021
N2 - Psychiatric and neurological disorders severely hamper patient’s quality of life. Despite their high unmet needs, the development of diagnostics and therapeutics has only made slow progress. This is due to limited evidence on the biological basis of these disorders in humans. Synapses are essential structural units of neurotransmission, and neuropsychiatric disorders are considered as “synapse diseases”. Thus, a translational approach with synaptic physiology is crucial to tackle these disorders. Among a variety of synapses, excitatory glutamatergic synapses play central roles in neuronal functions. The glutamate,-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) is a principal component of glutamatergic neurotransmission; therefore, it is considered to be a promising translational target. Here, we review the limitations of current diagnostics and therapeutics of neuropsychiatric disorders and advocate the urgent need for the promotion of translational medicine based on the synaptic physiology of AMPAR. Furthermore, we introduce our recent translational approach to these disorders by targeting at AMPARs.
AB - Psychiatric and neurological disorders severely hamper patient’s quality of life. Despite their high unmet needs, the development of diagnostics and therapeutics has only made slow progress. This is due to limited evidence on the biological basis of these disorders in humans. Synapses are essential structural units of neurotransmission, and neuropsychiatric disorders are considered as “synapse diseases”. Thus, a translational approach with synaptic physiology is crucial to tackle these disorders. Among a variety of synapses, excitatory glutamatergic synapses play central roles in neuronal functions. The glutamate,-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) is a principal component of glutamatergic neurotransmission; therefore, it is considered to be a promising translational target. Here, we review the limitations of current diagnostics and therapeutics of neuropsychiatric disorders and advocate the urgent need for the promotion of translational medicine based on the synaptic physiology of AMPAR. Furthermore, we introduce our recent translational approach to these disorders by targeting at AMPARs.
KW - AMPA receptor
KW - PET probe
KW - ednonerpic maleate
KW - synapse, synaptic plasticity
KW - translational medicine
UR - http://www.scopus.com/inward/record.url?scp=85099892295&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099892295&partnerID=8YFLogxK
U2 - 10.2183/PJAB.97.001
DO - 10.2183/PJAB.97.001
M3 - Article
C2 - 33431723
AN - SCOPUS:85099892295
VL - 97
SP - 1
EP - 21
JO - Proceedings of the Japan Academy Series B: Physical and Biological Sciences
JF - Proceedings of the Japan Academy Series B: Physical and Biological Sciences
SN - 0386-2208
IS - 1
ER -